Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Pancreatic Necrosis and Pancreatic Abscess : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Acknowledgments
Multimedia
References

Related Articles
Abdominal Abscess




Patient Education
Liver, Gallbladder, and Pancreas Center

Pancreatitis Overview

Pancreatitis Causes

Pancreatitis Symptoms

Pancreatitis Treatment




Author: Alan BR Thomson, MD, MSc, PhD, Professor, Department of Medicine, Division of Gastroenterology, University of Alberta Faculty of Medicine

Alan BR Thomson is a member of the following medical societies: American Federation for Aging Research, American Federation for Clinical Research, American Gastroenterological Association, American Geriatrics Society, American Physiological Society, Canadian Association of Gastroenterology, Gastroenterology Research Group, New York Academy of Sciences, and Royal Society of Medicine

Coauthor(s): Eric R Frizzell, MD, Instructor of Medicine, Uniformed Services University of the Health Sciences; Consulting Staff, Department of Medicine, Division of Gastroenterology, Walter Reed Army Medical Center

Editors: Jose A Perez, Jr, MD, MSEd, Director of Medical Education, Residency Program Director, Associate Professor, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Kern Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Douglas M Heuman, MD, FACP, Director of Hepatology, McGuire Veterans Affairs Medical Center, Professor, Department of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University School of Medicine; Alex J Mechaber, MD, FACP, Assistant Dean for Medical Curriculum, Associate Professor of Medicine, Division of General Internal Medicine, University of Miami Miller School of Medicine; Julian Katz, MD, Clinical Professor of Medicine, Drexel University College of Medicine; Consulting Staff, Department of Medicine, Section of Gastroenterology and Hepatology, Hospital of the Medical College of Pennsylvania

Author and Editor Disclosure

Synonyms and related keywords: infected pseudocyst, severe pancreatitis, PA, acute necrotizing pancreatitis, ANP

Background

Although there can be overlap in the characterization of infections in the pancreas, recognizing the different terms used in describing this complication of acute pancreatitis is important. A pancreatic abscess (PA) is a collection of pus resulting from tissue necrosis, liquefaction, and infection. Infected necrosis refers to bacterial contamination of necrotic pancreatic tissue in the absence of abscess formation. A pseudocyst is a peripancreatic fluid collection containing high concentrations of pancreatic enzymes within a defined fibrous wall and lacking an epithelial lining.

Pancreatic abscess is a late complication of acute necrotizing pancreatitis (ANP), occurring more than 4 weeks after the initial attack. The mortality rate associated with pancreatic abscess is generally less than that of infected necrosis. The mortality rate of pancreatitis may exceed 20% or more with infected pancreatic necrosis and is largely related to sepsis and multiorgan failure.

Pathophysiology

ANP is the most severe end of a spectrum of inflammation associated with pancreatitis. Inflammation causes cell death with resultant devitalized tissue, which is likely to become infected. The amount of necrotic tissue is the strongest predictor of mortality in ANP. After pancreatic necrosis occurs, 3 potential outcomes exist, resolution, pseudocyst, or abscess.  The role of proinflammatory cytokines in this process is being vigorously examined. 

Pancreatic abscesses form through various mechanisms, including fibrous wall formation around fluid collections, penetrating peptic ulcers, and secondary infection of pseudocysts. Pseudocysts arise as a complication of ANP. Over a period of 3-4 weeks, sequestration of necrotic tissue occurs, forming a fibrous capsule without an epithelial lining. At any point after the initial injury in ANP, infection of necrotic tissue may occur, leading to abscess formation. When this occurs prior to the formation of the fibrous wall, it is termed infected necrosis. Pseudocysts and abscesses can be single or multiple and vary greatly in size.

Of note, pseudocyst formation is directly related to the degree of necrosis present. Approximately 3% of patients with acute pancreatitis develop pancreatic abscess.

Balthazar and Ranson's radiographic staging criteria predict the formation of pseudocysts and, therefore, abscesses.

  • Grade A – Normal pancreas
  • Grade B - Focal or diffuse enlargement
  • Grade C - Mild peripancreatic inflammatory changes
  • Grade D - Single fluid collection
  • Grade E - Two or more fluid collections or gas within the pancreas or within peripancreatic inflammation

In grade A, B, C, or D, the probability of abscess formation is less than 2%. With grade E disease (2 or more collections of peripancreatic fluid), the probability rises to 57%.

Frequency

United States

The incidence of pancreatitis is approximately 185,000 cases per year. At least 80% of cases are due to alcohol and cholelithiasis. ANP is reported by some to occur in approximately 20% of all episodes of pancreatitis. Although sterile necrosis may occur, a variable percentage develop infection of the necrotic tissue. Depending on the time course and the host's ability to encase the necrotic tissue, the lesion is either infected necrosis or an abscess.

Mortality/Morbidity

  • Some studies have indicated a worse prognosis in idiopathic acute pancreatitis compared to pancreatitis induced by alcohol or biliary stones.
  • Patients are at risk for sepsis and, ultimately, even death. The mortality rate approaches 100% if surgical intervention and drainage are not undertaken for infected necrosis or abscess.
  • Pseudocysts may result in prolonged abdominal pain, rupture leading to acute peritonitis, fistula formation, and erosion into vessels with acute hemorrhage. Pancreatic ascites or pleural effusion may result.
  • Pseudocysts or abscesses may also cause hollow viscus obstruction by compression of surrounding structures, including the colon, stomach, duodenum, and the common bile duct.

Sex

Differences in sexual predilection are based on the difference in frequency of causative factors of the pancreatitis.

  • Women are more likely to have gallstone pancreatitis than men.
  • Men have alcohol-induced pancreatitis more commonly than women.
  • A difference in the rate of abscess formation between men and women has not been clearly demonstrated.



History

  • Diagnosed pancreatitis with an unexpectedly prolonged course, hemodynamic instability, fever, failure of medical therapy, or the presence of fluid collections on CT scan all point to the possibility of necrosis and, potentially, abscess formation later in the course.
  • Abscess formation takes weeks, and infected pancreatic necrosis may be diagnosed earlier in the course.

Physical

  • Abdominal pain with or without a mass on palpation of the epigastrium is suggestive of parietal peritoneal irritation.
  • Classic physical examination findings, such as Grey-Turner sign or Cullen sign, are supposedly characteristic of pancreatitis but rarely are noted in clinical practice.
  • Other physical findings are nonspecific and include abnormal vital signs consistent with sepsis, abdominal guarding, and rebound tenderness.

Causes

  • The inciting events for pancreatitis are legion; however, cholelithiasis and alcohol account for more than 80% of cases in the developed world.
  • Peripancreatic fluid encased in a fibrinous capsule defines pseudocysts.
  • Superinfection of pseudocysts is one way that pancreatic abscesses may form, though pseudocysts are not a prerequisite for abscess formation.
  • Evidence suggests that colonic translocation of bacterial flora accounts for many cases of pancreatic infection.
  • The most typical organisms isolated from infected necrosis and abscesses are enteric bacteria and Candida species.



Abdominal Abscess


Lab Studies

  • No specific hematologic studies define infected necrosis or pancreatic abscess.
  • A persistently elevated white blood cell count with a left shift and positive blood cultures is suggestive of this diagnosis.
  • The degree of pancreatic enzyme elevation does not directly indicate the degree of necrosis.

Imaging Studies

  • The presence of air in necrotic tissue in a pseudocyst on imaging studies is specific for infection as well.
  • Abdominal CT scan with IV contrast; ultrasound, either endoscopic or transabdominal; and MRI (with gadolinium) are potential modes for imaging pancreatic necrosis or abscess. MRI is becoming the imaging study of choice due to concerns regarding the use of iodinated contrast, which is said, by some, to devitalize marginal tissue, increasing the burden of necrotic tissue.
  • The current criterion standard for initial evaluation is contrast-enhanced CT scan, which may reveal ischemic pancreatic tissue as evidenced by the lack of uptake of contrast. There is some suggestion that early CT scan may be detrimental in ANP, with IV contrast worsening ischemia.
  • Consider repeat imaging in all patients with ANP who develop worsening abdominal pain, develop signs or symptoms of obstruction, or have a prolonged clinical course.
  • MRI may be of some additional benefit in the acute evaluation of ANP; gadolinium does not cause a worsening of ischemia in experimental models.
  • Pancreatic necrosis appears as devitalized tissue with decreased IV contrast present on CT scan or MRI. A pancreatic pseudocyst has a rim of fibrous tissue surrounding a pocket of peripancreatic fluid.  
    • Earlier accumulations of fluid without the fibrous tissue are referred to as peripancreatic fluid collections, and this formerly was referred to as phlegmon.
    • Demonstrable necrotic tissue in the pseudocyst may exist. Typically, this develops more than 3 weeks after the initial bout of pancreatitis.

Procedures

  • CT-guided or ultrasound-guided needle aspiration  
    • The presence of either bacterial or fungal flora in pancreatic fluid collections usually aspirated via CT-guided needle biopsy is the sine qua non of pancreatic abscess. The presence of organisms on either Gram stain or culture is essential to establish a diagnosis of abscess.
    • Pancreatic fluid collections are frequent sequelae of pancreatitis, and endoscopic drainage of these collections is gaining acceptance as an alternative to surgical drainage. Endoscopic ultrasound (EUS)-guided drainage should be reserved for prepancreatic fluid collections located at the pancreatic tail. These fluid collections should be evaluated by EUS before attempts at endoscopic drainage.
  • Surgical drainage  
    • Sterile necrosis may be followed with serial CT-guided drainage and continued antibiotics.
    • Surgical drainage of infected necrosis or an abscess is the procedure for cure. Placement of indwelling drains after the initial procedure may be necessary for complete resolution.



Medical Care

  • Medical care generally is supportive, with attention paid to blood pressure and volume status.
  • The role of appropriate prophylactic antibiotic therapy remains controversial but has gained support in clinical practice. 
  • Guide the choice of antibiotics by the likely flora and degree of antibiotic penetration into the abscess and the other necrotic tissue.  
    • The most commonly isolated bacteria in pancreatic abscesses are enteric organisms, through translocation through the gut.
    • The most common pathogens are Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Staphylococcus aureus, Pseudomonas aeruginosa, Proteus mirabilis, and Streptococcus species.

Surgical Care

  • Endoscopic sphincterotomy plays a role in patients with a dilated common bile duct from an impacted stone at risk of impending cholangitis. Surgery in acute pancreatitis is used for cholecystectomy in the patient with gallstone pancreatitis, as well as for infected pancreatic necrosis, pancreatic abscess, pseudocysts, and traumatic pancreatitis with a ruptured duct system. 
  • Primary drainage of the abscess is the treatment of choice for pancreatic abscess.
  • Cases have been reported of medical treatment of pancreatic abscess in which death has not resulted; however, the standard of care is drainage involving an open procedure.
  • Case series have been reported of patients with an abscess who have been treated with CT-guided drainage tube placement, but these seem to show inferior results to open drainage. Recent advances in endoscopic treatment using EUS have made guided transgastric treatment of the complications of ANP possible. Pseudocyst drainage via the transgastric approach is now common. EUS-guided necrosectomy has been promising to date. In specialized centers, this is rapidly becoming the treatment of choice.  
    • CT-guided drainage has some role in patients who cannot tolerate an open procedure. EUS with transgastric drainage is another option.
    • Consideration can be given to medical management of nonsurgical candidates until their clinical status improves.

Consultations

  • Gastroenterology
  • General surgery
  • Interventional radiology

Diet

  • Nothing by mouth (NPO) or a jejunal feeding tube for total enteral nutrition (TEN) is initially recommended early for ANP. 
    • TEN may be used as prophylactic therapy for infected pancreatic necrosis, since it significantly decreases the incidence of pancreatic infectious complications and the frequency of multiple organ failure and mortality. 
    • No contraindication for enteral feeding exists if the pancreatitis has resolved.
  • If the course is prolonged, the institution of total parenteral nutrition (TPN) can be of benefit.

Activity

Patients generally are hospitalized and unable to perform usual activities.



Antibiotics are the primary medical therapy in pancreatic abscess, used for the control of bacteremia and sepsis. Supportive care with fluids is needed, and the use of vasopressors may be required.

Drug Category: Antibiotics

Patients typically are bacteremic and/or septic.

Drug NameImipenem and Cilastin (Primaxin)
DescriptionDOC because of broad coverage, excellent penetration, and best clinical data to support use.
Adult Dose500 mg IV q6h
Pediatric DoseNot recommended
ContraindicationsDocumented hypersensitivity; seizure disorder; PCN allergy
InteractionsCoadministration with cyclosporine may increase adverse CNS effects of both agents; coadministration with ganciclovir may result in generalized seizures
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsAdjust dose in renal insufficiency; avoid use in children <12 y; 50% anaphylaxis cross-reactivity in patients with anaphylaxis to penicillin; meropenem has lower incidence of seizure; decrease dose with real insufficiency

Drug NameCefuroxime (Ceftin)
DescriptionSecond-generation cephalosporin maintains gram-positive activity that first-generation cephalosporins have; adds activity against P mirabilis, Haemophilus influenzae, E coli, K pneumoniae, and Moraxella catarrhalis. Condition of patient, severity of infection, and susceptibility of microorganism determines proper dose and route of administration. Shown in clinical trials to decrease mortality rates in ANP. Whether antioxidant effect may play a role in efficacy is questionable.
Adult Dose0.75-1.5 g IV/IM q8h
Pediatric DoseChildren: 250 mg PO bid for 20 d
Adolescents: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsDisulfiramlike reactions may occur when alcohol is consumed within 72 h after taking cefuroxime; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patient receiving potent diuretics, such as loop diuretics; coadministration with aminoglycosides increases nephrotoxic potential
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsAdminister half dose if creatinine clearance is 10-30 mL/min and quarter dose if <10 mL/min; fungal and microorganism overgrowth may occur with prolonged therapy

Drug NameCeftazidime (Ceptaz, Fortaz, Tazicef, Tazidime)
DescriptionThird-generation cephalosporin with broad coverage and better gram-negative coverage than cefuroxime. Has antipseudomonal activity; however, resistance to ceftazidime is as high as 15%. Some data support use in combination with amikacin and metronidazole in ANP.
Adult Dose1-2 g IV q8-12h
Pediatric DoseNeonates: 30 mg/kg IV q12h
Infants and children: 30-50 mg/kg/dose IV q8h; not to exceed 6 g/d
Adolescents: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsNephrotoxicity may increase with aminoglycosides, furosemide, and ethacrynic acid; probenecid may increase ceftazidime levels
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsAdjust dose in renal impairment

Drug NameOfloxacin (Floxin)
DescriptionA pyridine carboxylic acid derivative with broad-spectrum bactericidal effect. All quinolones have good activity against common flora found in pancreatic abscess, with exception of Candida species.
Adult Dose0.5 g IV bid
Pediatric Dose<18 years: Not recommended
ContraindicationsDocumented hypersensitivity
InteractionsAntacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; ciprofloxacin reduces therapeutic effects of phenytoin; probenecid may increase ciprofloxacin serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT)
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsIn prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy

Drug NameTicarcillin, clavulanate potassium (Timentin)
DescriptionExtended-spectrum penicillin. Inhibits biosynthesis of cell-wall mucopeptide and is effective during stage of active growth.
Adult Dose3/0.1 g (ticarcillin 3 g and clavulanate 0.1 g)IV q6h
Pediatric Dose50 mg/kg as high as 3.1 g (ticarcillin 3 g and clavulanate 0.1 g) IV q6h
ContraindicationsDocumented hypersensitivity; severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis should not be treated with oral penicillin during acute stage
InteractionsTetracyclines may decrease effects of ticarcillin; high concentrations of ticarcillin may physically inactivate aminoglycosides if administered in same IV line; effects when administered concurrently with aminoglycosides are synergistic; probenecid may increase penicillin levels
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsPerform CBC counts prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients diagnosed with hepatic insufficiencies; perform urinalysis, BUN, and creatinine determinations during therapy, and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions

Drug NamePiperacillin/Tazobactam (Zosyn)
DescriptionAn extended-spectrum penicillin. Inhibits biosynthesis of cell-wall mucopeptide and is effective during stage of active multiplication.
Adult Dose3/0.375 g (piperacillin 3 g and tazobactam 0.375 g) IV q6h
Pediatric Dose75 mg/kg IV q6h
ContraindicationsDocumented hypersensitivity; severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis should not be treated with an oral penicillin during the acute stage
InteractionsTetracyclines may decrease effects of ticarcillin; high concentrations of ticarcillin may physically inactivate aminoglycosides if administered in same IV line; effects when administered concurrently with aminoglycosides are synergistic; probenecid may increase penicillin levels
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
PrecautionsPerform CBCs prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients diagnosed with hepatic insufficiencies; perform urinalysis, and BUN and creatinine determinations during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions



Further Outpatient Care

Transfer

  • Patients usually should be in an ICU setting because they may decompensate quickly and require aggressive treatment, including mechanical ventilation.

Complications

  • Fistula formation
    • Enterocutaneous following surgery
    • Entero-entero
    • Enterovascular
  • Recurrent pancreatitis
  • Bowel obstruction
  • Death

Patient Education

  • Inform patients about the common causes of pancreatitis.
  • Offer cholecystectomy to patients with gallstone pancreatitis if they are surgical candidates.
  • Provide counseling for patients to abstain from alcohol use.
  • Monitor patients for steatorrhea, and inform them about the potential for pancreatic insufficiency and the potential need for pancreatic enzyme and fat-soluble vitamin supplementation.
  • For excellent patient education resources, visit eMedicine's Liver, Gallbladder, and Pancreas Center. Also, see eMedicine's patient education article Pancreatitis.



Medical/Legal Pitfalls

  • Failure to image if pancreatitis is not improving
  • Failure to sample fluid collection, if possible, for evidence of necrosis or abscess
  • Failure to consider surgery for definitive treatment



The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.



Media file 1:  Contrast-enhanced CT scan of infected pancreatic pseudocyst.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  CT



  • Beger HG, Bittner R, Block S, Büchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology. Aug 1986;91(2):433-8. [Medline].
  • Beger HG, Rau BM. Severe acute pancreatitis: Clinical course and management. World J Gastroenterol. Oct 14 2007;13(38):5043-51. [Medline].
  • Büchler M, Malfertheiner P, Friess H, Isenmann R, Vanek E, Grimm H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology. Dec 1992;103(6):1902-8. [Medline].
  • D'Egidio A, Schein M. Surgical strategies in the treatment of pancreatic necrosis and infection. Br J Surg. Feb 1991;78(2):133-7. [Medline].
  • Dragonetti GC, Licht H, Rubin W. Pancreatitis. Evaluation and treatment. Prim Care. Sep 1996;23(3):525-34. [Medline].
  • Dubner H, Steinberg W, Hill M, Bassi C, Chardavoyne R, Bank S. Infected pancreatic necrosis and peripancreatic fluid collections: serendipitous response to antibiotics and medical therapy in three patients. Pancreas. Apr 1996;12(3):298-302. [Medline].
  • Dugernier T, Dewaele J, Laterre PF. Current surgical management of acute pancreatitis. Acta Chir Belg. Mar-Apr 2006;106(2):165-71. [Medline].
  • Gerzof SG, Banks PA, Robbins AH, Johnson WC, Spechler SJ, Wetzner SM, et al. Early diagnosis of pancreatic infection by computed tomography-guided aspiration. Gastroenterology. Dec 1987;93(6):1315-20. [Medline].
  • Gorbach SL, Bartlett JG, Blacklow NR. Infectious Diseases. 2nd ed. 1998:891-892.
  • Hookey LC, Debroux S, Delhaye M, Arvanitakis M, Le Moine O, Devière J. Endoscopic drainage of pancreatic-fluid collections in 116 patients: a comparison of etiologies, drainage techniques, and outcomes. Gastrointest Endosc. Apr 2006;63(4):635-43. [Medline].
  • Karimgani I, Porter KA, Langevin RE, Banks PA. Prognostic factors in sterile pancreatic necrosis. Gastroenterology. Nov 1992;103(5):1636-40. [Medline].
  • Kramer KM, Levy H. Prophylactic antibiotics for severe acute pancreatitis: the beginning of an era. Pharmacotherapy. May 1999;19(5):592-602. [Medline].
  • Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 1. 5th ed. 2000:839-840.
  • Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg. Jan 1998;175(1):76-83. [Medline].
  • Papachristou GI, Takahashi N, Chahal P, Sarr MG, Baron TH. Peroral endoscopic drainage/debridement of walled-off pancreatic necrosis. Ann Surg. Jun 2007;245(6):943-51. [Medline].
  • Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet. May 1993;176(5):480-3. [Medline].
  • Petrov MS, Kukosh MV, Emelyanov NV. A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications with total enteral nutrition. Dig Surg. 2006;23(5-6):336-44; discussion 344-5. [Medline].
  • Pitchumoni CS, Patel NM, Shah P. Factors influencing mortality in acute pancreatitis: can we alter them?. J Clin Gastroenterol. Oct 2005;39(9):798-814. [Medline].
  • Powell JJ, Campbell E, Johnson CD, Siriwardena AK. Survey of antibiotic prophylaxis in acute pancreatitis in the UK and Ireland. Br J Surg. Mar 1999;86(3):320-2. [Medline].
  • Robertson KW, Stewart IS, Imrie CW. Severe acute pancreatitis and pregnancy. Pancreatology. 2006;6(4):309-15. [Medline].
  • Rünzi M, Layer P. Nonsurgical management of acute pancreatitis. Use of antibiotics. Surg Clin North Am. Aug 1999;79(4):759-65, ix. [Medline].
  • Seewald S, Groth S, Omar S, Imazu H, Seitz U, de Weerth A, et al. Aggressive endoscopic therapy for pancreatic necrosis and pancreatic abscess: a new safe and effective treatment algorithm (videos). Gastrointest Endosc. Jul 2005;62(1):92-100. [Medline].
  • Varadarajulu S, Wilcox CM, Tamhane A, Eloubeidi MA, Blakely J, Canon CL. Role of EUS in drainage of peripancreatic fluid collections not amenable for endoscopic transmural drainage. Gastrointest Endosc. Dec 2007;66(6):1107-19. [Medline].
  • Witt H, Apte MV, Keim V, Wilson JS. Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology. Apr 2007;132(4):1557-73. [Medline].
  • Wyncoll DL. The management of severe acute necrotising pancreatitis: an evidence-based review of the literature. Intensive Care Med. Feb 1999;25(2):146-56. [Medline].
  • Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T, et al. Treatment strategy against infection: clinical outcome of continuous regional arterial infusion, enteral nutrition, and surgery in severe acute pancreatitis. J Gastroenterol. Aug 2007;42(8):681-9. [Medline].

Pancreatic Necrosis and Pancreatic Abscess excerpt

Article Last Updated: Jun 12, 2008